

## Addendum

**Addendum: Real-world survival analysis by tumor mutational burden in non-small cell lung cancer: a multisite U.S. study**

**Connor Willis<sup>1</sup>, Hillevi Bauer<sup>1</sup>, Trang H. Au<sup>1</sup>, Jyothi Menon<sup>1</sup>, Sudhir Unni<sup>1</sup>, Dao Tran<sup>2</sup>, Zachary Rivers<sup>2</sup>, Wallace Akerley<sup>3</sup>, Matthew B. Schabath<sup>4</sup>, Firas Badin<sup>5</sup>, Ashley Sekhon<sup>6</sup>, Malini Patel<sup>7</sup>, Bing Xia<sup>8</sup>, Beth Gustafson<sup>9</sup>, John L. Villano<sup>10</sup>, John-Michael Thomas<sup>11</sup>, Solomon J. Lubinga<sup>12</sup>, Michael A. Cantrell<sup>13</sup>, Diana Brixner<sup>1</sup> and David Stenehjem<sup>1,2</sup>**

<sup>1</sup>Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA

<sup>2</sup>Department of Pharmacy Practice and Pharmaceutical Sciences, College of Pharmacy, University of Minnesota, Duluth, MN, USA

<sup>3</sup>Department of Internal Medicine, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA

<sup>4</sup>Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

<sup>5</sup>Department of Hematology and Oncology, Baptist Health Medical Group, Lexington, KY, USA

<sup>6</sup>Department of Radiation Oncology, MetroHealth Medical Center, Cleveland, OH, USA

<sup>7</sup>Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

<sup>8</sup>Department of Medicine, Kenneth Norris Jr. Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA

<sup>9</sup>Precision Oncology Program, Saint Luke's Cancer Institute, Kansas City, MO, USA

<sup>10</sup>Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY, USA

<sup>11</sup>US Medical Oncology, Bristol Myers Squibb, Princeton, NJ, USA

<sup>12</sup>Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA

<sup>13</sup>Global Medical Oncology, Bristol Myers Squibb, Princeton, NJ, USA

**Published:** December 06, 2022

**Copyright:** © 2022 Willis et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**This article has an addendum:** This study proceeded with institutional IRB approvals at each participating cancer center. Due to the retrospective nature of this project, a waiver of informed consent was approved by each of the listed local IRBs.

Original article: Oncotarget. 2022; 13:257–270. <https://doi.org/10.18632/oncotarget.28178>